Clinical trial
Safety and Efficacy Study of Denosumab in Patients With Recurrent or…
NCT00396279 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00396279 |
|---|---|
| Title | Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone |
| Official title | An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects With Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | GCT, Giant Cell Tumor of Bone |
| Intervention type | Biological, Dietary Supplement |
| Interventions | Denosumab, Calcium/Vitamin D |
| Enrollment | 37 |
| Start date | Jul 10, 2006 |
| Primary completion | Apr 7, 2008 |
| Completion | Feb 1, 2011 |
| First posted | Nov 6, 2006 |
| Last update posted | Nov 8, 2022 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: